Propanc Biopharma raised 100 million USD from Hexstone Capital to develop a portfolio of digital assets, including Bitcoin, Ethereum, Solana, and Dogecoin. They aim to enhance their flagship oncology therapy PRP, with first human trials expected in 2026.
Despite the positive funding news, Propanc’s stock has faced challenges, falling by 43% in the last month, with shares dropping 4% on announcement day.
Leave a Reply